Successfully Integrating Radium Ra 223 Dichloride Injection Into a Urology Practice

por McMahon, Gregory C., Brown, Gordon A.
Publicado en Rev Urol (2017)

Utilization of individualized prostate cancer and genomic biomarkers for the practicing urologist

por McMahon, Gregory C., Brown, Gordon A., Mueller, Thomas J.
Publicado en Rev Urol (2017)

Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Gr...

por McGinley, Kathleen F, McMahon, Gregory C, Brown, Gordon A
Publicado en Rev Urol (2015)

PROSTATIC URETHRAL BIOPSY HAS LIMITED UTILITY IN COUNSELING PATIENTS REGARDING FINAL URETHRAL MARGIN STATUS DURING ORTHOTOPIC NEOBLADDER RECONSTRUCTION

por Kassouf, Wassim, Spiess, Philippe E., Brown, Gordon A., Liu, Ping, Grossman, H. Barton, Dinney, Colin P. N., Kamat, Ashish M.
Publicado en J Urol (2008)

Barriers to accessing urethroplasty

por Consolo, Michael J., Syed, Kirin K., Robison, Christopher, McFadden, Jacob, Shalowitz, David I., Brown, Gordon A., Sussman, David O., Figler, Bradley D.
Publicado en Rev Urol (2016)

P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors

por Kassouf, Wassim, Spiess, Philippe E., Brown, Gordon A., Munsell, Mark F., Grossman, H. Barton, Siefker-Radtke, Arlene, Dinney, Colin P.N., Kamat, Ashish M.
Publicado 2007

ABILITY OF CLINICAL GRADE TO PREDICT FINAL PATHOLOGIC STAGE IN UPPER URINARY TRACT TRANSITIONAL CELL CARCINOMA: IMPLICATIONS FOR THERAPY

por BROWN, GORDON A., MATIN, SURENA F., BUSBY, J. ERIK, DINNEY, COLIN P. N., GROSSMAN, H. BARTON, PETTAWAY, CURTIS A., MUNSELL, MARK F., KAMAT, ASHISH M.
Publicado 2007

The Role of Radical Cystectomy in Patients with Clinical T4b Bladder Cancer

por Black, Peter C., Dinney, Colin P.N., Brown, Gordon A., Kassouf, Wassim, Siefker-Radtke, Arlene O., Munsell, Mark F., Grossman, H. Barton, Kamat, Ashish M.
Publicado 2010

Is Vascular Endothelial Growth Factor Modulation a Predictor of the Therapeutic Efficacy of Gefitinib for Bladder Cancer?

por Kassouf, Wassim, Brown, Gordon A., Black, Peter C., Fisher, Mark B., Inamoto, Teruo, Luongo, Tony, Gallagher, David, Bar-Eli, Menashe, McConkey, David J., Adam, Liana, Dinney, Colin P. N.
Publicado en J Urol (2008)

DISTINCTIVE EXPRESSION PATTERN OF ErbB FAMILY RECEPTORS SIGNIFY AN AGGRESSIVE VARIANT OF BLADDER CANCER

por Kassouf, Wassim, Black, Peter C., Tuziak, Tomasz, Bondaruk, Jolanta, Lee, Sangkyou, Brown, Gordon A., Adam, Liana, Wei, Caimiao, Baggerly, Keith, Bar-Eli, Menashe, McConkey, David, Czerniak, Bogdan, Dinney, Colin P.
Publicado 2007

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines

por Shore, Neal D., Antonarakis, Emmanuel S., Cookson, Michael S., Crawford, E. David, Morgans, Alicia K., Albala, David M., Hafron, Jason, Harris, Richard G., Saltzstein, Daniel, Brown, Gordon A., Henderson, Jonathan, Lowentritt, Benjamin, Spier, Jeffrey M., Concepcion, Raoul
Publicado en Prostate (2020)